CA2782015C - Topical ophthalmic compositions and methods for the treatment of macular degeneration - Google Patents
Topical ophthalmic compositions and methods for the treatment of macular degeneration Download PDFInfo
- Publication number
- CA2782015C CA2782015C CA2782015A CA2782015A CA2782015C CA 2782015 C CA2782015 C CA 2782015C CA 2782015 A CA2782015 A CA 2782015A CA 2782015 A CA2782015 A CA 2782015A CA 2782015 C CA2782015 C CA 2782015C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- cyclodextrin
- compound
- beta
- macular degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 29
- 230000000699 topical effect Effects 0.000 title abstract description 17
- 238000000034 method Methods 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 229920000858 Cyclodextrin Polymers 0.000 claims description 52
- 229940126062 Compound A Drugs 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 22
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 17
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 16
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 208000027073 Stargardt disease Diseases 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 8
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 8
- -1 hydroxyl- Chemical group 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 159000000000 sodium salts Chemical group 0.000 claims description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 2
- 229940031576 hydroxypropylbetadex (0.58-0.68 ms) Drugs 0.000 claims 11
- DZLKUJDRGIBINH-ZMGQIDSOSA-N 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10,15,20,25,30,35-hexakis(4-sulfobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonic acid Chemical compound O([C@@H]([C@@H]([C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]3[C@@H](COCCCCS(O)(=O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](COCCCCS(O)(=O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](COCCCCS(O)(=O)=O)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](COCCCCS(O)(=O)=O)O[C@@H]([C@@H]([C@H]3O)O)O3)O[C@@H]2COCCCCS(O)(=O)=O)O)[C@H](COCCCCS(O)(=O)=O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]3[C@@H](COCCCCS(O)(=O)=O)O1 DZLKUJDRGIBINH-ZMGQIDSOSA-N 0.000 claims 9
- 229910019142 PO4 Inorganic materials 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 6
- 239000010452 phosphate Substances 0.000 claims 6
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical class [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 claims 2
- 150000002634 lipophilic molecules Chemical class 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 description 20
- FMASHOOOLPDQTK-UHFFFAOYSA-L disodium;4-(4-sulfonatobutoxy)butane-1-sulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCCOCCCCS([O-])(=O)=O FMASHOOOLPDQTK-UHFFFAOYSA-L 0.000 description 14
- 210000001525 retina Anatomy 0.000 description 14
- 235000020945 retinal Nutrition 0.000 description 14
- 239000011604 retinal Substances 0.000 description 14
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000013543 active substance Substances 0.000 description 8
- 230000004300 dark adaptation Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 6
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229960005280 isotretinoin Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 150000004492 retinoid derivatives Chemical class 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000004382 visual function Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WJIGGYYSZBWCGC-MRXNPFEDSA-N (1r)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol Chemical compound NCC[C@@H](O)C1=CC=CC(OCC2CCCCC2)=C1 WJIGGYYSZBWCGC-MRXNPFEDSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002571 electroretinography Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 230000016732 phototransduction Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- UOZXOFPVRJVDGV-UHFFFAOYSA-N sodium;4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound [Na].OS(=O)(=O)CCCCOCCCCS(O)(=O)=O UOZXOFPVRJVDGV-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28574509P | 2009-12-11 | 2009-12-11 | |
| US61/285,745 | 2009-12-11 | ||
| PCT/US2010/059719 WO2011072141A1 (en) | 2009-12-11 | 2010-12-09 | Compositions and methods for the treatment of macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2782015A1 CA2782015A1 (en) | 2011-06-16 |
| CA2782015C true CA2782015C (en) | 2020-08-25 |
Family
ID=44145918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2782015A Active CA2782015C (en) | 2009-12-11 | 2010-12-09 | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US9814701B2 (enExample) |
| JP (4) | JP5885670B2 (enExample) |
| CA (1) | CA2782015C (enExample) |
| WO (1) | WO2011072141A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101321742B (zh) | 2005-05-26 | 2012-08-29 | 神经元系统公司 | 用于治疗视网膜疾病的组合物和方法 |
| CA2782015C (en) * | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| WO2014100425A1 (en) | 2012-12-20 | 2014-06-26 | Aldexa Therapeutics, Inc. | Peri-carbinols |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| MX2015009444A (es) * | 2013-01-25 | 2016-04-15 | Aldeyra Therapeutics Inc | Trampas novedosas en el tratamiento de la degeneracion macular. |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| BR112018069533A2 (pt) | 2016-02-28 | 2019-04-16 | Aldeyra Therapeutics, Inc. | tratamento de condições alérgicas oculares com ciclodextrinas |
| EP3454858A4 (en) * | 2016-05-09 | 2020-01-15 | Aldeyra Therapeutics, Inc. | COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| JP2021533154A (ja) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
| CA3132466A1 (en) * | 2019-03-05 | 2020-09-10 | Cornell University | Compositions of matter with activity to remove lipofuscin from retinal cells |
| JP7706758B2 (ja) * | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN115697336A (zh) | 2020-05-13 | 2023-02-03 | 奥尔德拉医疗公司 | 药物制剂及其用途 |
| WO2022092896A1 (ko) * | 2020-10-29 | 2022-05-05 | 주식회사 피노바이오 | 시신경 보호 대상인 환자에게 점안제로 투여하기 위한 약학 조성물 |
Family Cites Families (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| SU50906A1 (ru) | 1935-12-20 | 1936-11-30 | А.И. Бурляев | Веретено дл пр дильных машин |
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| JPS6192592A (ja) | 1984-10-12 | 1986-05-10 | Norin Suisansyo Shokuhin Sogo Kenkyusho | 分岐サイクロデキストリンの製造方法 |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| US5032392A (en) | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
| NZ225045A (en) | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU8942491A (en) | 1990-10-22 | 1992-05-20 | Bausch & Lomb Incorporated | Method and composition for cleaning contact lenses |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| JP2746832B2 (ja) | 1993-05-14 | 1998-05-06 | 大鵬薬品工業株式会社 | 眼局所抗アレルギー剤 |
| GB9318431D0 (en) | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| US5767109A (en) | 1993-10-20 | 1998-06-16 | Sanchez; Robert A. | Complexing urushiols |
| US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| JPH08175985A (ja) | 1994-12-26 | 1996-07-09 | Lion Corp | 点眼剤 |
| JP3297969B2 (ja) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| FR2742053B1 (fr) | 1995-12-06 | 1998-03-06 | Chauvin Lab Sa | Compositions pharmaceutiques a base de mequitazine |
| JP3736916B2 (ja) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの消毒用組成物とその用途 |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| CN1228084A (zh) | 1996-08-01 | 1999-09-08 | 道农业科学公司 | 具有杀菌活性的4－取代的喹啉衍生物 |
| WO1998005661A1 (en) | 1996-08-06 | 1998-02-12 | Pfizer Inc. | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| US6191127B1 (en) | 1997-05-02 | 2001-02-20 | Schering Aktiengesellschaft | Substituted heterocycles and their use in medicaments |
| JPH10306022A (ja) | 1997-05-06 | 1998-11-17 | Lion Corp | 点眼剤 |
| GB2327672A (en) | 1997-07-23 | 1999-02-03 | Merck & Co Inc | 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine |
| EP1012151B1 (en) | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| JP3568108B2 (ja) | 1999-07-28 | 2004-09-22 | 松下電器産業株式会社 | デジタル地図の位置情報伝達方法とそれを実施する装置 |
| WO2001035958A1 (en) | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
| WO2001041757A1 (en) * | 1999-12-10 | 2001-06-14 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP2001318350A (ja) | 2000-05-11 | 2001-11-16 | Lion Corp | コンタクトレンズ用溶液 |
| JP4748289B2 (ja) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | 点眼剤、眼科用組成物及び吸着抑制方法 |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| CA2416228C (en) * | 2002-01-15 | 2010-07-13 | Olsonet Communications Corporation | Communication nodes for use with a wireless ad-hoc communication network |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20040198828A1 (en) | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
| EP3326623A1 (en) | 2003-03-14 | 2018-05-30 | University of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| DE602004030103D1 (de) | 2003-04-18 | 2010-12-30 | Advanced Medicine Res Inst | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| JP2005132834A (ja) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | キノリン誘導体 |
| WO2005035506A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規インダゾール誘導体 |
| WO2005040151A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| KR20060109947A (ko) | 2003-11-20 | 2006-10-23 | 오쎄라 파마슈티걸즈, 인크. | 황반 변성 및 다른 안과 질환의 개선 |
| JP2005187407A (ja) | 2003-12-25 | 2005-07-14 | Lion Corp | アレルギー眼疾患用眼科組成物 |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| CA2555261A1 (en) | 2004-02-17 | 2005-09-01 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| JP2006008568A (ja) | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | ＩｇＥ抗体抑制剤および食品 |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| WO2006049968A1 (en) | 2004-10-28 | 2006-05-11 | Merck & Co., Inc. | Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| US20100160304A1 (en) | 2005-01-19 | 2010-06-24 | Dainippon Sumitomo Pharma Co., Ltd | Aromatic sulfone compound as aldosterone receptor modulator |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| CN1830964B (zh) | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途 |
| WO2006122183A2 (en) | 2005-05-10 | 2006-11-16 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
| CN101321742B (zh) | 2005-05-26 | 2012-08-29 | 神经元系统公司 | 用于治疗视网膜疾病的组合物和方法 |
| EP1967186B1 (en) | 2005-12-27 | 2015-03-11 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
| US20070297981A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
| JP4466875B2 (ja) | 2006-04-05 | 2010-05-26 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
| BRPI0710737A2 (pt) | 2006-04-14 | 2011-05-10 | Prana Biotechnology Ltd | uso de compostos pb-10 33 éteis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos |
| JP5194218B2 (ja) | 2006-06-05 | 2013-05-08 | 株式会社メニコンネクト | 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ |
| EP2079699A1 (en) | 2006-07-25 | 2009-07-22 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
| CN101522671A (zh) | 2006-08-14 | 2009-09-02 | 先灵公司 | 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法 |
| ES2953390T3 (es) | 2006-08-31 | 2023-11-10 | Adare Pharmaceuticals Inc | Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos |
| CL2007003065A1 (es) | 2006-10-24 | 2008-01-25 | Wyeth Corp | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros |
| US8158609B1 (en) | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
| US20080241256A1 (en) | 2007-03-30 | 2008-10-02 | Liisa Kuhn | Targeted active agent delivery system based on calcium phosphate nanoparticles |
| US8490764B2 (en) | 2007-05-30 | 2013-07-23 | Margaret Simester | Portable storage and changing station |
| US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
| CN101889017B (zh) | 2007-10-05 | 2013-11-27 | 奥克塞拉有限公司 | 用于治疗疾病的烷氧基化合物 |
| NZ587376A (en) | 2008-02-11 | 2012-06-29 | Univ Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
| CA2733966A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| BRPI0919920A2 (pt) | 2008-10-22 | 2016-02-16 | Acucela Inc | compostos para tratamento de doenças e desordens oftálmicas |
| EP2358660A2 (en) | 2008-11-11 | 2011-08-24 | Novartis AG | Salts of fingolimod |
| WO2010107525A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| US20110105450A1 (en) | 2009-06-05 | 2011-05-05 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
| US20100331315A1 (en) | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
| WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| WO2011078204A1 (ja) | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
| BR112012021086A2 (pt) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos |
| US8575221B2 (en) | 2010-03-17 | 2013-11-05 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
| JP2011203665A (ja) | 2010-03-26 | 2011-10-13 | Ophtecs Corp | コンタクトレンズの白濁解消用製剤及び白濁解消方法 |
| CA2808909A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
| CA2816420C (en) | 2010-10-29 | 2018-01-16 | Najib Babul | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol |
| US9718796B2 (en) | 2011-01-12 | 2017-08-01 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| US10463687B2 (en) | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
| EP2670439B1 (en) | 2011-01-31 | 2019-03-13 | PVAC Medical Technologies Ltd. | Active principle for mitigating undesired medical conditions |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| CN104159594A (zh) | 2011-10-13 | 2014-11-19 | 托马斯·盖德克 | 用于皮肤病治疗的凯莫瑞c15肽的局部制剂 |
| US9817701B2 (en) | 2011-12-12 | 2017-11-14 | International Business Machines Corporation | Threshold computing in a distributed computing system |
| US20130190500A1 (en) | 2011-12-12 | 2013-07-25 | Neuron Systems, Inc. | Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| GB201200192D0 (en) | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| EP2879683B1 (en) | 2012-08-01 | 2020-01-22 | Lewis and Clark Pharmaceuticals, Inc. | N-alkyl-alkynyladenosine-5-uronamide compounds as agonists of a2a receptor |
| KR102467714B1 (ko) | 2012-11-08 | 2022-11-16 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
| WO2014100425A1 (en) | 2012-12-20 | 2014-06-26 | Aldexa Therapeutics, Inc. | Peri-carbinols |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| BR112015017246B1 (pt) | 2013-01-23 | 2022-11-29 | Semnur Pharmaceuticals, Inc | Composição farmacêutica aquosa injetável, seu uso e seringa |
| MX2015009444A (es) | 2013-01-25 | 2016-04-15 | Aldeyra Therapeutics Inc | Trampas novedosas en el tratamiento de la degeneracion macular. |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| EP3151818A4 (en) | 2014-06-04 | 2018-05-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| NO2721710T3 (enExample) | 2014-08-21 | 2018-03-31 | ||
| MX372723B (es) | 2014-09-02 | 2020-06-19 | Bhupinder Singh | Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento. |
| TW201628622A (zh) | 2014-11-17 | 2016-08-16 | 製藥公司 | Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合 |
| US10363231B2 (en) | 2014-11-24 | 2019-07-30 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| US9953187B2 (en) | 2014-11-25 | 2018-04-24 | Honeywell International Inc. | System and method of contextual adjustment of video fidelity to protect privacy |
| KR20240049684A (ko) | 2015-04-15 | 2024-04-16 | 베이진 엘티디 | B-raf 키나아제 억제제의 말레에이트 염, 결정질 형태, 제조방법, 및 이의 용도 |
| HK1256143A1 (zh) | 2015-08-21 | 2019-09-13 | Aldeyra Therapeutics, Inc. | 醛結合物和其用途 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| GB201522441D0 (en) | 2015-12-18 | 2016-02-03 | Midatech Pharma Wales Ltd | Sustained release cyclosporine-loaded microparticles |
| BR112018069533A2 (pt) | 2016-02-28 | 2019-04-16 | Aldeyra Therapeutics, Inc. | tratamento de condições alérgicas oculares com ciclodextrinas |
| EP3454858A4 (en) | 2016-05-09 | 2020-01-15 | Aldeyra Therapeutics, Inc. | COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE |
| WO2017214201A1 (en) | 2016-06-06 | 2017-12-14 | Thesan Pharmaceuticals, Inc. | Formulations for substituted 3-pyrrolidines, compositions containing, and uses of, same |
| AU2017317524A1 (en) | 2016-08-22 | 2019-02-21 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
| CA3032609A1 (en) | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and methods of use thereof |
| JP7030345B2 (ja) | 2016-09-28 | 2022-03-07 | メディコン ファーマシューティカルズ，インコーポレイテッド | 眼の状態を処置する組成物および方法 |
| WO2018067860A1 (en) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| JP7073358B2 (ja) | 2016-10-12 | 2022-05-23 | ピー・エス・セラピー・リミテッド | 人工涙液、コンタクトレンズ及び薬剤担体組成物並びにその使用方法 |
| GB2556082A (en) | 2016-11-18 | 2018-05-23 | Warneford Healthcare Ltd | Ophthalmic composition |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US10664688B2 (en) | 2017-09-20 | 2020-05-26 | Google Llc | Systems and methods of detecting and responding to a visitor to a smart home environment |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| CA3194972A1 (en) | 2017-12-14 | 2019-06-20 | Lutron Technology Company Llc | Privacy mode for a wireless audio device |
| WO2020018498A1 (en) | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
| WO2020028820A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| JP2021533154A (ja) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US10915995B2 (en) | 2018-09-24 | 2021-02-09 | Movidius Ltd. | Methods and apparatus to generate masked images based on selective privacy and/or location tracking |
| WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
| US20210317385A1 (en) | 2018-10-02 | 2021-10-14 | Aldeyra Therapeutics, Inc. | Contact lens solutions and kits |
| US20220133697A1 (en) | 2018-12-05 | 2022-05-05 | Aldeyra Therapeutics, Inc. | Injectable formulations |
| JP7706758B2 (ja) | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| EP4028015A4 (en) | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | OPHTHALMIC FORMULATIONS OF METHOTREXATE |
| WO2021195211A1 (en) | 2020-03-24 | 2021-09-30 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating respiratory disorders and viral infections |
| CN115551507A (zh) | 2020-04-13 | 2022-12-30 | 奥尔德拉医疗公司 | 用于治疗肺、肝脏和肾脏疾病、病症或病况的喹啉化合物 |
| CN115697336A (zh) | 2020-05-13 | 2023-02-03 | 奥尔德拉医疗公司 | 药物制剂及其用途 |
| JP2023529840A (ja) | 2020-06-04 | 2023-07-12 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患バイオマーカーおよび処置するための該バイオマーカーの使用 |
| CN112541870A (zh) | 2020-12-07 | 2021-03-23 | 北京大米科技有限公司 | 一种视频处理的方法、装置、可读存储介质和电子设备 |
| US20220211691A1 (en) | 2021-01-07 | 2022-07-07 | Aldeyra Therapeutics, Inc. | Treatment of dry eye disease |
| WO2022150580A1 (en) | 2021-01-07 | 2022-07-14 | Aldeyra Therapeutics, Inc. | Treatment of dry eye disease |
| CN112800947A (zh) | 2021-01-27 | 2021-05-14 | 上海电气集团股份有限公司 | 视频监控方法、系统、电子设备及存储介质 |
| EP4362930A4 (en) | 2021-07-02 | 2025-09-24 | Aldeyra Therapeutics Inc | HETEROCYCLIC ALDEHYDE-SCAPPING COMPOUNDS AND THEIR USES |
-
2010
- 2010-12-09 CA CA2782015A patent/CA2782015C/en active Active
- 2010-12-09 US US13/514,769 patent/US9814701B2/en active Active
- 2010-12-09 JP JP2012543284A patent/JP5885670B2/ja active Active
- 2010-12-09 WO PCT/US2010/059719 patent/WO2011072141A1/en not_active Ceased
-
2014
- 2014-12-18 JP JP2014255880A patent/JP6063916B2/ja active Active
-
2016
- 2016-04-19 JP JP2016083344A patent/JP6378242B2/ja active Active
- 2016-12-19 JP JP2016245212A patent/JP2017052799A/ja active Pending
-
2017
- 2017-10-12 US US15/782,470 patent/US20180092882A1/en not_active Abandoned
-
2023
- 2023-09-01 US US18/241,598 patent/US12097188B2/en active Active
-
2024
- 2024-07-29 US US18/786,975 patent/US20250144080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6063916B2 (ja) | 2017-01-18 |
| CA2782015A1 (en) | 2011-06-16 |
| WO2011072141A1 (en) | 2011-06-16 |
| JP2013513612A (ja) | 2013-04-22 |
| JP2016130266A (ja) | 2016-07-21 |
| JP2017052799A (ja) | 2017-03-16 |
| US20180092882A1 (en) | 2018-04-05 |
| US12097188B2 (en) | 2024-09-24 |
| US20120302601A1 (en) | 2012-11-29 |
| US20250144080A1 (en) | 2025-05-08 |
| JP5885670B2 (ja) | 2016-03-15 |
| US9814701B2 (en) | 2017-11-14 |
| JP6378242B2 (ja) | 2018-08-22 |
| JP2015057437A (ja) | 2015-03-26 |
| US20240148700A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12097188B2 (en) | Compositions and methods for the treatment of macular degeneration | |
| CN107362157B (zh) | 用于医学和兽医学的眼科药物组合物 | |
| JP5315252B2 (ja) | 眼科用薬物の輸送に有用なゲル | |
| Bito | Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds | |
| US20110105450A1 (en) | Ophthalmic formulations of fluticasone and methods of use | |
| JP6888754B2 (ja) | インサイチュでゲルを形成する医薬製剤 | |
| JP2018531292A6 (ja) | インサイチュでゲルを形成する医薬製剤 | |
| JPH08509205A (ja) | β−シクロデキストリン誘導体及び治療剤を含んだ眼のための局所組成物 | |
| KR101396731B1 (ko) | 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제 | |
| JP2023154024A (ja) | 眼病態を治療するための方法および組成物 | |
| KR20110042282A (ko) | 눈 전면에 대한 지속 전달제로서의 인 시츄 겔화 시스템 | |
| US11166977B2 (en) | Compositions for treating meibomian gland dysfunction | |
| CN116211804A (zh) | 熊去氧胆酸脂质组合物及其应用 | |
| JP5087242B2 (ja) | ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム | |
| JPWO2006098292A1 (ja) | 眼疾患治療剤 | |
| KR0159640B1 (ko) | 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형 | |
| JP2013103919A (ja) | クロルフェニラミンマレイン酸塩を含有する徐放性フィルム製剤 | |
| WO2007013591A1 (ja) | ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151127 |